Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AbbVie sees 80% discounting

Executive Summary

Discounts due to biosimilar competition have risen as high as 80% in Europe, according to AbbVie chairman and chief executive officer Richard Gonzalez. Noting that Remicade (infliximab) and Enbrel (etanercept) were the “analogs” that AbbVie had used to plan for the onset of biosimilar competition to its Humira (adalimumab) brand in Europe, he observed that discounting on infliximab and etanercept “ranges from as low as 10% to as high as around 80%”, with “the higher discounting seen in the Nordic tender countries”.

You may also be interested in...



Five Competitors Confirmed On Canadian Adalimumab

Multiple competitors have now confirmed the launch of Canadian biosimilar versions of the world’s biggest-selling drug, Humira.

FDA Approves Mylan’s Humira Biosimilar

Mylan’s Hulio has become the sixth biosimilar version of Humira to be approved by the US FDA. However, all of these adalimumab biosimilars face a wait until 2023 before they can enter the market.

Japan Approves First Humira Biosimilar

Japan has approved its first biosimilar rival to Humira. Mylan is set to market the Fujifilm Kyowa Kirin Biologics adalimumab biosimilar, having already launched the product as Hulio in Europe.

Related Content

UsernamePublicRestriction

Register

GB001441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel